Access Pharma, AMAG Announce US License Deal for MuGard

ACCESS PHARMACEUTICALS, INC. ACCP, an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with AMAG Pharmaceuticals, Inc. AMAG related to the commercialization of MuGard™ in the US and its territories.  Under the terms of the license agreement, Access will receive an upfront licensing fee of $3.3 million and a tiered, double digit royalty on net sales of MuGard in the licensed territories.  AMAG will also purchase existing MuGard inventory from Access.  MuGard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Oral mucositis is a common side effect of cancer treatments, with approximately 400,000 patients developing the condition each year.